Asahi Kasei files complaint against Endo over Xiaflex supplies

2 October 2019

Japanese drugmaker Asahi Kasei Pharma (TYO: 3407) has filed a complaint requesting a preliminary injunction against Endo Ventures Limited and Endo Pharmaceuticals (Nasdaq: ENDP) to require Ireland-incorporated Endo to continue to supply the company with Xiaflex (collagenase clostridium histolyticum), for the treatment of Dupuytren’s contracture.

The matter was filed in the US District Court for the Southern District of New York on September 30, said Asahi Kasei, whose shares rose 3.3% to $20.41 following the announcement on Monday.

Asahi Kasei has a long-term development, commercialization and supply agreement with Endo which requires Endo to exclusively supply the company with the pharmaceutical in Japan. Until now, Endo has supplied the drug to the Asahi Kasei which has been selling Xiaflex in Japan under the supply agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK